H2FPEF Scores Are Increased in Patients with NASH Cirrhosis and Are Associated with Post-liver Transplant Heart Failure

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2024 May 23

PMID 38782854

Authors

David G Koch

Don C Rockey

Sheldon S Litwin

Ryan J Tedford

Affiliations

Soon will be listed here.

Abstract

Introduction: Patients with cirrhosis are at risk for cardiac complications such as heart failure, particularly heart failure with preserved ejection fraction (HFpEF) due to left ventricular diastolic dysfunction (LVDD). The H2FPEF score is a predictive model used to identify patients with HFpEF. Our primary aim was to assess the H2FPEF score in patients with cirrhosis and determine its potential to identify patients at risk for heart failure after liver transplant.

Methods: This was a cohort study of patients undergoing liver transplant for cirrhosis from January 2010 and October 2018 who had a pre-transplant transthoracic echocardiogram.

Results: 166 cirrhosis subjects were included in the study. The majority were men (65%) and Caucasian (85%); NASH was the most common cause of cirrhosis (41%) followed by alcohol (34%). The median H2FPEF score was 2.0 (1.0-4.0). Patients with NASH cirrhosis had higher H2FPEF scores (3.22, 2.79-3.64) than those with alcohol induced cirrhosis (1.89, 1.5-2.29, p < 0.001) and other causes of cirrhosis (1.73, 1.28-2.18, p < 0.001). All subjects with a H2FPEF score > 6 had NASH cirrhosis. There was no association between the H2FPEF scores and measures of severity of liver disease (bilirubin, INR, or MELD score). Patients with heart failure after liver transplant had higher H2FPEF scores than those without heart failure (4.0, 3.1-4.9 vs. 2.3, 2.1-2.6, respectively; p = 0.015), but the score did not predict post-transplant mortality.

Conclusion: H2FPEF scores are higher in cirrhosis patients with NASH and appear to be associated with post-transplant heart failure, but not death.

References

Moller S, Henriksen J . Cardiovascular complications of cirrhosis. Gut. 2008; 57(2):268-78. DOI: 10.1136/gut.2006.112177. View

Izzy M, Oh J, Watt K . Cirrhotic Cardiomyopathy After Transplantation: Neither the Transient Nor Innocent Bystander. Hepatology. 2018; 68(5):2008-2015. DOI: 10.1002/hep.30040. View

Younossi Z, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H . Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9(6):524-530.e1. DOI: 10.1016/j.cgh.2011.03.020. View

Williams C, Stengel J, Asike M, Torres D, Shaw J, Contreras M . Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2010; 140(1):124-31. DOI: 10.1053/j.gastro.2010.09.038. View

Izzy M, VanWagner L, Lin G, Altieri M, Findlay J, Oh J . Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology. 2019; 71(1):334-345. PMC: 7288530. DOI: 10.1002/hep.30875. View

Yoon K, Liu H, Lee S . Cirrhotic Cardiomyopathy. Curr Gastroenterol Rep. 2020; 22(9):45. DOI: 10.1007/s11894-020-00783-1. View

VanWagner L, Ning H, Whitsett M, Levitsky J, Uttal S, Wilkins J . A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: The CAR-OLT score. Hepatology. 2017; 66(6):1968-1979. PMC: 5696007. DOI: 10.1002/hep.29329. View

Chung G, Lee J, Lee H, Kim M, Yim J, Choi S . Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. Atherosclerosis. 2018; 272:137-144. DOI: 10.1016/j.atherosclerosis.2018.03.027. View

Salah H, Pandey A, Soloveva A, Abdelmalek M, Diehl A, Moylan C . Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci. 2021; 6(11):918-932. PMC: 8617573. DOI: 10.1016/j.jacbts.2021.07.010. View

10.

Lee S, Song M, Kim S, Ahn H . Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis. Clin Mol Hepatol. 2018; 24(4):409-416. PMC: 6313020. DOI: 10.3350/cmh.2018.0034. View

11.

Byrne C, Targher G . Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab. 2021; 24 Suppl 2:28-43. DOI: 10.1111/dom.14484. View

12.

Billey C, Billet S, Robic M, Cognet T, Guillaume M, Vinel J . A Prospective Study Identifying Predictive Factors of Cardiac Decompensation After Transjugular Intrahepatic Portosystemic Shunt: The Toulouse Algorithm. Hepatology. 2019; 70(6):1928-1941. DOI: 10.1002/hep.30934. View

13.

Zardi E, Zardi D, Chin D, Sonnino C, Dobrina A, Abbate A . Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase. J Cardiol. 2015; 67(2):125-30. DOI: 10.1016/j.jjcc.2015.04.016. View

14.

Vernon G, Baranova A, Younossi Z . Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34(3):274-85. DOI: 10.1111/j.1365-2036.2011.04724.x. View

15.

Fudim M, Zhong L, Patel K, Khera R, Abdelmalek M, Diehl A . Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries. J Am Heart Assoc. 2021; 10(22):e021654. PMC: 8751938. DOI: 10.1161/JAHA.121.021654. View

16.

Spann A, Coe C, Ajayi T, Montgomery G, Shwetar M, Oje A . Cirrhotic cardiomyopathy: Appraisal of the original and revised criteria in predicting posttransplant cardiac outcomes. Liver Transpl. 2022; 28(8):1321-1331. PMC: 9288516. DOI: 10.1002/lt.26460. View

17.

Koepp K, Reddy Y, Obokata M, Sorimachi H, Verbrugge F, Jain C . Identification of Patients with Preclinical Heart Failure with preserved Ejection Fraction Using the HFPEF Score. Nat Cardiovasc Res. 2022; 1(1):59-66. PMC: 9164289. DOI: 10.1038/s44161-021-00005-5. View

18.

Anstee Q, Mantovani A, Tilg H, Targher G . Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018; 15(7):425-439. DOI: 10.1038/s41575-018-0010-0. View

19.

Ge J, Lai J, Boike J, German M, Jest N, Morelli G . Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post-Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study. Liver Transpl. 2020; 27(3):329-340. PMC: 8053375. DOI: 10.1002/lt.25949. View

20.

Mantovani A, Byrne C, Benfari G, Bonapace S, Simon T, Targher G . Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2022; 79(2):180-191. DOI: 10.1016/j.jacc.2021.11.007. View